BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
But in all fairness, that's kind of what we did with our patients if they were not cisplatinum eligible. We didn't give them cisplatinum-based therapy because they can't receive it. We don't give them carboplatinum. And then we observed them in the adjuvant setting. So that's the control arm for the Volga study.
0
💬
0
Comments
Log in to comment.
There are no comments yet.